News

Amy Kunchok, MD, staff neurologist at the Mellen Center for Multiple Sclerosis and Research at Cleveland Clinic, discussed a recent talk she gave that highlighted the different phenotypes of AQP-IgG NMOSD and MOGAD.

Neurology News Network for the week ending December 18, 2021. [WATCH TIME: 3 minutes]

Argenx’s antibody fragment to target the neonatal Fc receptor is the first in its class, with its approval backed by data from the phase 3 ADAPT trial.

Pharma Two B anticipates filing a new drug application to the FDA for the investigational treatment in 2022.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 17, 2021.

The chief medical officer of Cognetivity outlined a new integrated cognitive assessment that takes only 5 minutes to complete on an iPad. [WATCH TIME: 6 minutes]

Mind Moments™, a podcast from NeurologyLive®, brings you an exclusive interview with Anton Porsteinsson, MD.

Two parallel studies will evaluate the BioXcel Therapeutics’ drug’s effectiveness as an acute therapy in treating a full spectrum of agitation in 300 patients with AD.

Findings represent the most comprehensive metabolic profiling of this patient population as a function of body mass index.

The post-marketing study of aducanumab (Aduhelm) is expected to enroll 1300 patients with early Alzheimer, with the final protocol to be submitted to the FDA in March 2022, and plans to initiate patient screening in May 2022.

The director of the Joseph Epstein Center for Emergency Medicine Research discussed the complexities of diagnosing migraine in the emergency department and whether institutions should reevaluate their internal processes to do so. [WATCH TIME: 3 minutes]

Clinicians have begun to incorporate more holistic ways to approach the treatment of multiple sclerosis symptoms by focusing on better overall health, exercising, and dieting.

The FDA has set a prescription drug user fee act goal date of September 28, 2022, for the investigational treatment from TG Therapeutics.

Chris Kalafatis, MD, MRCPsych, discussed a new tool, the Integrated Cognitive Assessment, developed by Cognetivity, and its potential for patients with dementias and multiple sclerosis.

The director of the epilepsy center at Cleveland Clinic Neurological Institute spoke on one of the studies he coauthored that were presented at AES 2021. [WATCH TIME: 4 minutes]

Over a 10-year period, apomorphine sublingual film was projected to be dominant in 70% of patients compared with apomorphine hydrochloride injection and 71% vs levodopa inhalation powder.

The director of the Tuberous Sclerosis Clinic at Cincinnati Children’s provided insight on promising drug developments for tuberous sclerosis complex and other notable priorities within the space.

Results from a recent study further suggest that using digital cognitive behavior therapy for insomnia, or dCBT-I, during pregnancy may be effective in preventing postpartum depression and anxiety.

Investigators used cross-sectional data from the observational population-based cohort of the Maastricht Study, calculating LIBRA scores with 12 dementia risk and protective factors.

The director of Cleveland Clinic’s Epilepsy Center at the Cleveland Clinic Neurological Institute discussed the need for specificity and artificial intelligence for patients with epilepsy. [WATCH TIME: 4 minutes]

Jessica Fesler, MD, MEd, staff epileptologist, Cleveland Clinic, offered insight on the future of seizure apps and how if improved, they could alter the treatment of patients with epilepsy.

The director of the Joseph Epstein Center for Emergency Medicine Research discussed the origin behind her multinational study evaluating the outcome of headache in emergency departments. [WATCH TIME: 3 minutes]

The newly adopted AASM guidelines are designed to help health care providers treating obstructive sleep apnea know when to discuss referral for upper airway or bariatric surgery evaluation with their patients.

The medical director of the Epilepsy program at the University of Toronto discussed her presentation at AES 2021 regarding the need to change how clinicians view and treat patients with developmental epileptic encephalopathies.

Ellie Harrington, lecturer in genetic counseling, provides answers for patients with ALS who might be unfamiliar with genetic testing and counseling.

The CEO of ZZ Biotech outlined the design of the phase 2 trial of 3KA-APC, which will enroll 16 patients with amyotrophic lateral sclerosis. [WATCH TIME: 4 minutes]

Here's what is coming soon to NeurologyLive®.

Statistical significance was observed for both the MycarinG study’s primary and secondary end points in a population of 200 patients with myasthenia gravis treated with the UCB agent.